EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 11, 2012, Pages 7348-7357

  Wang, Jia lin ^a   Liu, Yu ling ^a   Li, Ying ^a   Dai, Wen bing ^b   Guo, Zhao ming ^a   Wang, Zhao hui ^a   Zhang, Qiang ^b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPHRIN RECEPTOR A2; LIPOSOME; SODIUM CHLORIDE; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG STABILITY; DRUG UPTAKE; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; LIGHT SCATTERING; MALE; MASS SPECTROMETRY; NICK END LABELING; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; RETINA FLUORESCEIN ANGIOGRAPHY; SUBRETINAL NEOVASCULARIZATION; THIN LAYER CHROMATOGRAPHY; TOXICITY; ULTRAVIOLET SPECTROPHOTOMETRY; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG CARRIERS; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; LIPOSOMES; MALE; MICROSCOPY, CONFOCAL; POLYETHYLENE GLYCOLS; RATS; RECEPTOR, EPHA2;

EID: 84872016241     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9955     Document Type: Article

References (26)

1. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11:67-115.
2. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
3. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:141-143.
4. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene. 2000; 19:6043-6052.
5. Cheng N, Brantley DM, Liu H, et al. Blockade of EphA2 receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res. 2002;1:2-11.
6. Chen J, Hicks D, Brantley-Sieders D, et al. Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res. 2006;82:664-673.
7. Pandey A, Shao H, Mark RM, Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis. Science. 1995;268:567-569.
8. Daniel TO, Stein E, Cerretti DP, St John PL, Robert B, Abrahamson DR. Elk and LERK-2 in developing kidney and microvascular endothelial assembly. Kidney Int. 1996; 57(suppl):S73-S81.
9. Flenniken AM, Gale NW, Yancopoulos GD, Wilkinson DG. Distinct and overlapping expression patterns of ligands for Eph-receptor tyrosine kinases during mouse embryogenesis. Dev Biol. 1996;179:382-401.
10. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem. 2002; 277:46974-46979.
11. Berlin V, Haseltine WA. Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J Biol Chem. 1981;256:4747-4756.
12. Gilleron M, Marechal X, Montaigre D, Franczak J, Neviere R, Lancel S. NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun. 2009;388:727-731.
13. Zhang LL, Yu DY, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. 2002;62:2034-2042.
14. Colombo T, Donelli MG, Urso R, Dallarda S, Bartosek I, Guaitani A. Doxorubicin toxicity and pharmacokinetics in old and young rats. Exp Gerontol. 1989;24:159-171.
15. Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissue with liposomes. Adv Drug Deliver Rev. 1999;40:89-102.
16. Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stability liposomes. Invest Ophthalmol Vis Sci. 2002;43:253-259.
17. Xiong XB, Huang Y, Lu WL, Zhang H, Zhang X, Zhang Q. Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res. 2005;22:933-939.
18. Harrigan PR, Wang KF, Redelmeier TE, Wheeler JJ, Cullis PR. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta. 1993;1149:329-338.
19. Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J. Controlled Release. 2010;141:183-192.
20. Liu HA, Liu YL, Ma ZZ, Wang JC, Zhang Q. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laserinduced murine CNV model. Invest Ophthalmol Vis Sci. 2011; 52:4789-4794.
21. Campos M, Amara J, Becerra SP, Fariss RN. A novel imaging technique for experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006;47:5163-5170.
22. Edelman JL, Castro MR. Quantitative image analysis of laserinduced choroidal neovascularization in rat. Exp Eye Res. 2000;71:523-533.
23. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010;6:12-21.
24. Hu T, Le QH, Wu ZY, Wu W. Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-β-hydroxybutyrate microspheres. J Pharm Biomed Anal. 2007;43:263-269.
25. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992;33:3125-3130.
26. Bochot A, Fattal E. Liposomes for intravitreal drug delivery: a state of the art. J Controlled Release. 2012;161:628-634.